Regeneron Earnings Prime, Biotech Big Edges Larger

Regeneron Prescription drugs (REGN) on on Thursday reported adjusted earnings of $9.89 per share on $2.53 billion in gross sales for its first quarter. In response, Regeneron inventory edged increased.


On common, analysts polled by FactSet anticipated Regeneron to earn $8.74 per share on $2.53 billion in gross sales.

Within the year-earlier interval, Regeneron earnings had been $6.60 per share and the corporate reported $1.83 billion in gross sales.

The biotech firm didn’t present full-year EPS or gross sales steerage. Analysts known as for adjusted earnings of $46.62 per share and $12 billion in gross sales.

In premarket buying and selling on the stock market today, Regeneron inventory rose 0.7%.

Extra to observe.

Observe Allison Gatlin on Twitter at @IBD_AGatlin.


InMode Stock Rises After IBD 50 Stalwart Posts Triple-Digit Profit Growth

Jazz Expects To Buy GW Pharma — This Month — And Eyes Breakout

Options Trading: How To Start Using Options, How To Manage Risk

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Get Full Access To IBD Stock Lists And Ratings

Source link

Hits: 0

Leave a Reply

Your email address will not be published. Required fields are marked *